"We believe there is a large patient population that is underserved right now. T cell-targeting therapies, to be honest, are great. Look at the clinical data with PD-1s. They're fantastic for patients, but T-cell infiltration in all human cancer is only 25 percent."

The FDA released final guidance to help sponsors develop systemic drugs for HIV-1 pre-exposure prophylaxis (PrEP). The guidance provides nonclinical and clinical recommendations, with a focus on long-acting systemic drugs intended to prevent sexually acquired infections.

Grants received by biopharma companies, July 1 - October 24, 2019

The top 10 biopharma stock gainers and losers for the week of Oct. 21–25, 2019.

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes.

Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.

While the general markets are leaning toward positive territory following a quiet summer period, the enthusiasm for biopharma equities remains muted. One of the most closely monitored therapeutic areas is oncology. Earlier this year, public companies developing innovative medicines in that area had enjoyed strong support; however, investors now appear to be more selective in backing companies in that sector.

Year-to-date money raised in public, private and other financings of biopharma companies.

Abalos Therapeutics GmbH raised €12 million (US$13.2 million) in series A funding to advance a distinctive approach to harnessing viruses for immuno-oncology applications.